CU6 - Media and Industry News, page-945

“TLX591 looks well ahead.”
“At this stage Cu67 looks like being fairly close to pluvicto”

Not from the research I’ve been looking at.

Treatment emergent adverse events (TEAE’s) all grades
Cu67 Secure Trial 33%
Pluvicto Vision Trial 83%
TLX-591 ProstACT Trial 90%

TEAE’s Grade 3 and above
Cu67 13%
Pluvicto 38%
TLX-591 55%

Haematological TEAE’s Grade 3 or higher
Cu67 13%
Pluvicto 8%
TLX-591 55%

When it comes to overall survival rates yes TLX-591 is higher than Pluvicto however both are considerably lower than the results achieved from the Enza-P trial combining Pluvicto with Enzalutamide (an ARPI)

So given Clarity have announced that the next phase of the Secure trial will also include Enza in combination with Cu67, it will be very interesting to see who ends up at the top of OS table along with the best safety profile.